About the Study

Episodic migraine: A study on erenumab treatment in children and adolescent

This study is for children/teens: • 12-17 years old • Who have up to 14 headaches in a month (with at least 4 being classified as a migraine) The purpose of the OASIS PEDIATRIC (EM) study is to evaluate the safety and effectiveness of a study medicine called erenumab to reduce the frequency of episodic migraine headaches. In this study, erenumab is being compared to a placebo, which allows researchers to evaluate the effects of the study medicine. Participants have to be willing to have two injections under the skin once a month, and follow all study instructions. Study participants will have approximately 8 monthly visits to the clinic, and if interested in the optional extension phase, there will be an additional 10 visits. The visits take about 2-3 hours.

Interested in learning more?

Full Study Name: Erenumab Study for the Treatment of Episodic Migraines in Children Ages 12-17